NCT05933889Recruiting
Single and Combined Modality Trans-Oral Robotic Surgery in Early Oropharyngeal Cancer
Single and Combined Modality Trans-Oral Robotic Surgery in Early Oropharyngeal Cancer: Exploring the Impact of Surgical Margins on Local Disease Recurrence: The SCORE Study
Source: ClinicalTrials.gov · Last updated 7 Aug 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Multi-centre retrospective observational cohort study with optional exploratory radiomic study (international) and prospective molecular analysis studies (UK only).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 250 (estimated)
- First submitted
- 14 Jun 2023
- Start date
- 19 Dec 2023
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- Royal Marsden NHS Foundation Trust
- Diseases
- Head and neck cancer
- NCT number
- NCT05933889
What you commit to
- Study type: Observational
- Planned participants: 250
- From 19 Dec 2023 to the primary completion date, 31 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior history of head and neck cancer or radiation therapy at any time
Other illness
- Known distant metastatic disease.
- Nasopharyngeal, thyroid, cutaneous, and non-SCC head and neck cancers.
Other
- Moderate to advanced stage T3-T4 oropharyngeal SCC
- TORS performed for diagnostic, recurrent, or palliative intentions.
Who the study is looking for
- 18 years and older.
- Primary tumour within the oropharynx (defined as tonsil, soft palate, tongue base, lateral and posterior oropharyngeal walls)
- Histologically confirmed squamous cell carcinoma.
- P16 positive or negative tumours
- Index cancer treated with TORS with or without adjuvant therapy.
- Early pT1-T2 stage oropharyngeal SCC
- TORS performed on or before 31st December 2021
- For the exploratory analysis only:
- Ability to consent to molecular analysis study
- Ability to consent to radiomic/ imaging study (as required for international centres)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Royal Marsden Hospital NHS Foundation Trust Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.